Public Health Pharmacogenomics and the Design Principles for Global Public Goods – Moving Genomics to Responsible Innovation

Farah Huzair, Ozdemir V (Lead Author), Alexander Borda-rodriguez, Dove, Edward, Ferguson L.R., Manolopoulos G.V., Masellis M, Milius D, Louise Warnich, S Srivastava

Research output: Contribution to journalArticlepeer-review

Abstract

“Evidence in the clinical care context differs from evidence in the public health and health policy domains. It is often difficult to apply rigid hierarchies of evidence to public health policy.”
Tikki Pang [1]

“Pharmacogenomics and personalized medicine knowledge cannot be siloed into a pure and narrow technology lens alone. The field’s ontology requires a nuanced understanding of the complex linkages between the science, technology, society, and politics ecosystem and therefore must be situated within a broader framework.”
Edward S. Dove [2]

“The trend has been to use data derived from African populations to build research programmes and enhance individual careers in more affluent communities with little or no consideration for the populations from which this material was derived.”
Jantina de Vries and Michael Pepper [3]
Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalCurrent Pharmacogenomics and Personalized Medicine
Volume11
Issue number1
Publication statusPublished - 24 Mar 2013

Keywords

  • genomics and development
  • genomics without borders
  • global governance of biotechnology innovation and uncertainty
  • P5 medicine
  • public health pharmacogenomics
  • responsible innovation
  • STS and organizations
  • theranostic medicine

Fingerprint

Dive into the research topics of 'Public Health Pharmacogenomics and the Design Principles for Global Public Goods – Moving Genomics to Responsible Innovation'. Together they form a unique fingerprint.

Cite this